GSK Buys Nuvalent for $10.6 Billion to Strengthen Lung Cancer Pipeline

Britain’s GSK has agreed to buy US biotech firm Nuvalent for $10.6 billion in cash, marking the drugmaker’s largest acquisition in more than a decade and giving it control over two late-stage lung cancer treatments. The deal values Nuvalent at roughly $124 a share, a 40 percent premium to its closing price, and sent the target company’s shares surging 39 percent in premarket trading while GSK shares slipped 2.6 percent in London.

Nuvalent, founded in 2017 by Harvard chemist Matthew Shair and listed on Nasdaq in 2021, specializes in targeted therapies for subsets of non-small cell lung cancer driven by specific genetic mutations. Its two most advanced candidates, zidesamtinib and neladalkib, are under FDA review with decisions expected in September and November. GSK said the medicines could launch later this year and carry “blockbuster potential,” each potentially generating several billion dollars in annual sales. The acquisition also brings an earlier-stage asset and a preclinical portfolio.

Company executives framed the purchase as a strategic response to an impending revenue gap. GSK’s top-selling HIV medicine is set to lose market exclusivity starting in 2028, and the Nuvalent assets are expected to provide immediate new growth in oncology. Chief executive Luke Miels called the two lead products “potential best-in-class” options that would expand treatment choices for patients with limited alternatives. Analysts at Barclays noted that the transaction adds clinically advanced programs to GSK’s existing cancer business, though they questioned aspects of the price tag.

The transaction continues a pattern of large pharmaceutical companies acquiring smaller innovators rather than building equivalent pipelines internally. Nuvalent’s largest shareholder, New York-based Deerfield Management, stands to receive a substantial payout, while founder Shair’s roughly 2 percent stake could translate to nearly $200 million. Such windfalls for early investors and executives have become routine in biotech exits, even as the resulting medicines often reach patients at premium prices set by the acquiring corporation.

GSK described the purchase as its biggest ever, surpassing the scale of its 2014 asset swap with Novartis. The move comes as major drugmakers race to refresh portfolios ahead of patent expirations across multiple franchises. Whether the new lung cancer therapies will be priced to maximize revenue or to maximize access remains to be seen, and regulators will ultimately determine how quickly and broadly they reach the roughly 4,000 US patients whose tumors carry the relevant mutations.